Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event
Co-Diagnostics (Nasdaq: CODX) said its Chief Commercialization Officer participated in Salt Lake Business Journal’s 2026 Medical Devices and Innovation Roundtable on Aug. 13. The company also disclosed a 510(k) premarket notification submission to the FDA for its Co-Dx PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro instrument, pending FDA clearance.
How this was made
The 30-second read
Why it matters
The disclosed 510(k) submission supports a potential path to FDA clearance for the Flu A/B and RSV multiplex test, but the article does not state acceptance, review timing, or expected decision date.
Market read
Traders get an incremental regulatory milestone (510(k) submission) tied to a specific multiplex test, but no decision or timeline is provided.
What to watch
The platform is explicitly not yet cleared or authorized for sale, so near-term revenue impact is likely deferred until clearance and launch execution.
Background
Co-Diagnostics is developing a PCR point-of-care platform and multiplex respiratory tests, with FDA clearance required before sale.
Ticker impact
Co-Diagnostics says it submitted a 510(k) for its Co-Dx PCR Flu A/B and RSV multiplex test on the Co-Dx PCR Pro instrument.
Limited immediate impact expected, but clearance timing could drive volatility around FDA feedback and any subsequent launch milestones.
The release discloses a regulatory submission and commercialization-readiness activities, but provides no FDA decision, timeline, or acceptance outcome.
Market effects
Highlights ongoing competitive push in molecular diagnostics and point-of-care PCR platforms, with AI and interoperability themes at industry events.
Utah medical-device ecosystem visibility, but no direct regional financial linkage disclosed.
Mentions pursuing international regulatory authorizations, implying potential future expansion beyond the US if cleared.
Counterpoint
A conference participation item plus a 510(k) submission may not move the stock until FDA acceptance or substantive feedback is received.
Key entities
- public_companyCo-Diagnostics, Inc.
Molecular diagnostics company (Nasdaq: CODX) submitting a 510(k) for a multiplex respiratory test on its PCR Pro instrument.
- regulatorFDA
Regulatory body reviewing the 510(k) submission; clearance outcome determines commercialization.
- productCo-Dx PCR Pro instrument
Instrument platform referenced as the basis for the submitted multiplex test.
